1. Yi G., Wang Y., Wang L. et al. Capturing the Abnormal Brain Network Activity in Early Parkinsons Disease with Mild Cognitive Impairment based on Dynamic Functional Connectivity. IEEE Transactions on Neural Systems and Rehabilitation Engineering. 2023;31;1238-1247. DOI: 10.1109/TNSRE.2023.3243035 EDN: PQVFJW
2. Broom D.M. Evolution of pain. In Pain: its nature and management in man and animals. Ed. Soulsby, Lord and Morton, D. Royal Society of Medicine International Congress Symposium Series. 2001;246:17-25.
3. Walters E.T., de C Williams A.C. Evolution of mechanisms and behaviour important for pain. Philosophical Transactions of the Royal Society B. 2019;374(1785):20190275. DOI: 10.1098/rstb.2019.0275
4. Nesse R.M., Schulkin J. An evolutionary medicine perspective on pain and its disorders. Philosophical Transactions of the Royal Society B. 2019;374(1785):20190288. DOI: 10.1098/rstb.2019.0288
5. Strausfeld N.J., Hirth F. Introduction to ‘Origin and evolution of the nervous system. Philosophical Transactions of the Royal Society B. 2015;370(1684):20150033. DOI: 10.1098/rstb.2015.0033
6. Wenzel J.M., Oleson E.B., Gove W.N. et al. Phasic Dopamine Signals in the Nucleus Accumbens that Cause Active Avoidance Require Endocannabinoid Mobilization in the Midbrain. Current Biology. 2018;28(9):1392-1404.e5. DOI: 10.1016/j.cub.2018.03.037
7. Langston J.W. The Parkinson’s complex: Parkinsonism is just the tip of the iceberg. Annals of Neurology. 2006;59:591-596. DOI: 10.1002/ana.20834
8. Blanchet P.J., Brefel-Courbon C. Chronic pain and pain processing in Parkinson’s disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2018;87(Pt.B):200-206. DOI: 10.1016/j.pnpbp.2017.10.010
9. Antonini A., Tinazzi M., Abbruzzese G. et al. Pain in Parkinson’s disease: facts and uncertainties. European Journal of Neurology. 2018;25(7):917-e969. DOI: 10.1111/ene.13624
10. Nguy V., Barry B.K., Moloney N. et al. The associations between physical activity, sleep, and mood with pain in people with Parkinson’s disease: an observational cross-sectional study. Journal of Parkinson’s Disease. 2020;10:1161-1170. DOI: 10.3233/JPD-201938 EDN: QCMQBE
11. Brunner R., Gerberich A. Managing Pain in Parkinson’s Disease. Practical Pain Management. 2021;21(1). URL: https://www.medcentral.com/neurology/parkinsons/managing-pain-parkinson-disease (accessed 24.11.2023).
12. Gandolfi M., Geroin C., Antonini A. et al. Understanding and treating pain syndromes in Parkinson’s disease. International Review of Neurobiology. 2017;134:827-858. DOI: 10.1016/bs.irn.2017.05.013
13. Rukavina K., Leta V., Sportelli C. et al. Pain in Parkinson’s disease: new concepts in pathogenesis and treatment. Current Opinion in Neurology. 2019;32:579-588. DOI: 10.1097/WCO.0000000000000711 EDN: UPBTBY
14. Suppa A., Leone C., Di Stasio F. et al. Pain-motor integration in the primary motor cortex in Parkinson’s disease. Brain Stimulation. 2017;10(4):806-816. DOI: 10.1016/j.brs.2017.04.130
15. Sung S., Vijiaratnam N., Chan D.W.C. et al. Parkinson disease: A systemic review of pain sensitivities and its association with clinical pain and response to dopaminergic stimulation. Journal of the Neurological Sciences. 2018;395:172-206. DOI: 10.1016/j.jns.2018.10.013
16. Joseph C., Jonsson-Lecapre J., Wicksell R. et al. Pain in persons with mild-moderate Parkinson’s disease: a cross-sectional study of pain severity and associated factors. International Journal of Rehabilitation Research. 2019;42(4):371-376. DOI: 10.1097/MRR.0000000000000373
17. Back F.P., Carobrez A.P. Periaqueductal gray glutamatergic, cannabinoid and vanilloid receptor interplay in defensive behavior and aversive memory formation. Neuropharmacology. 2018;135:399-411. DOI: 10.1016/j.neuropharm.2018.03.032
18. Bourbia N., Pertovaara A. Involvement of the periaqueductal gray in the descending antinociceptive effect induced by the central nucleus of amygdala. Physiological Research. 2018;67(4):647-655. DOI: 10.33549/physiolres.933699
19. Wang Q.P., Nakai Y. The dorsal raphe: an important nucleus in pain modulation. Brain Research Bulletin. 1994;34(6):575-585. DOI: 10.1016/0361-9230(94)90143-0
20. Ham S., Lee Y.I., Jo M. et al. Hydrocortisone-induced parkin prevents dopaminergic cell death via CREB pathway in Parkinson’s disease model. Scientific Reports. 2017;7(1):525. DOI: 10.1038/s41598-017-00614-w EDN: FQCGWS
21. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. Elsevier. Academic Press. 2005:367.
22. Kilkenny C., Browne W., Cuthill I.C. et al. Animal research: Reporting in vivo experiments: The ARRIVE guidelines. British Journal of Pharmacology. 2010;160(7):1577-1579. DOI: 10.1111/j.1476-5381.2010.00872.x
23. Орлов А.И. Прикладная статистика. М.: Изд-во “Экзамен”. 2004. 656 c. EDN: WONLTZ
24. Hynd M.R., Scott H.L., Dodd P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochemistry International. 2004;45(5):583-595. DOI: 10.1016/j.neuint.2004.03.007
25. Lucas D.R., Newhouse J.P. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Archives of ophthalmology. 1957;58(2):193-201. DOI: 10.1001/archopht.1957.00940010205006
26. Olney J.W. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science. 1969;164(3880):719-721. DOI: 10.1126/science.164.3880.719 EDN: IDGWSH